Publications by authors named "Irini Flouri"

Claim this Profile
L
Long-term comparative analysis of secukinumab versus TNFα inhibitors in patients with spondyloarthritis: treatment persistence is differentially affected by disease phenotype, obesity and sex.
Irini D Flouri, Argyro Repa, Nestor Avgoustidis, Sofia Pitsigavdaki, Eleni Kalogiannaki

Arthritis Res Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries.
Romain Aymon, Denis Mongin, Romain Guemara, Zubeyir Salis, Johan Askling, Irini Flouri

Arthritis Rheumatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of clinical factors predicts successful glucocorticoid withdrawal in systemic lupus erythematosus (SLE): results from a multicentre, retrospective cohort study.
Spyridon Katechis, Sofia Pitsigavdaki, Myrto Nikoloudaki, Ettore Silvagni, Argyro Repa, Irini Flouri

RMD Open· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Difficult-to-Manage Axial Spondyloarthritis.
Evgenia Emmanouilidou, Irini D Flouri, Antonios Bertsias, Eleni Kalogiannaki, George Bertsias

Mediterr J Rheumatol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression.
Sofia Pitsigavdaki, Myrto Nikoloudaki, Panagiotis Garantziotis, Ettore Silvagni, Argyro Repa, Irini Flouri

Ann Rheum Dis· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct long-term disease activity trajectories differentiate early on treatment with etanercept in both rheumatoid arthritis and spondylarthritis patients: a prospective cohort study.
Irini Flouri, Panagiota Goutakoli, Argyro Repa, Antonios Bertsias, Nestor Avgoustidis

Rheumatol Int· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of comorbidities differentially affect long-term functional evolution and disease activity in patients with 'difficult to treat' rheumatoid arthritis.
Antonios Bertsias, Irini D Flouri, Argyro Repa, Nestor Avgoustidis, Eleni Kalogiannaki

RMD Open· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Peripheral Blood Signature of Increased Th1 and Myeloid Cells Combined with Serum Inflammatory Mediators Is Associated with Response to Abatacept in Rheumatoid Arthritis Patients.
Panagiota Goutakoli, Garyfalia Papadaki, Argyro Repa, Nestor Avgoustidis, Eleni Kalogiannaki, Irini Flouri

Cells· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comorbidities Burden and Implementation of the Treat-to-Target Strategy in Predicting Real-World Patient Outcomes in Spondyloarthritides.
Irini D Flouri, Argyro Repa, Nestor Avgoustidis, Sofia Pitsigavdaki, Katerina Pateromichelaki

Mediterr J Rheumatol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost of Illness, Quality of Life, and Work Productivity in Axial Spondyloarthritis Patients Receiving Biological Treatments in Greece.
Nikolaos Kougkas, Charalambos Mylonas, Nestor Avgoustidis, Irini Flouri, Prodromos Sidiropoulos

Mediterr J Rheumatol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study.
Myrto Nikoloudaki, Dionysis Nikolopoulos, Sofia Koutsoviti, Irini Flouri, Noemin Kapsala

Front Immunol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Characteristics, Symptoms, and Risk Factors of Idiopathic Chilblains: A Systematic Review, Meta-Analysis, and Meta-Regression.
Areti K Kapnia, Styliani Ziaka, Leonidas G Ioannou, Irini Flouri, Petros C Dinas, Andreas D Flouris

Biology (Basel)· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline IgG-Fc N-glycosylation profile is associated with long-term outcome in a cohort of early inflammatory arthritis patients.
Thomas Sénard, Irini Flouri, Frano Vučković, Garyfalia Papadaki, Panagiota Goutakoli

Arthritis Res Ther· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study.
Antonios Bertsias, Nestor Avgoustidis, Ioannis Papalopoulos, Argyro Repa, Nikolaos Kougkas, Irini Flouri

Arthritis Res Ther· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases.
Matthew L Thomas, Gavin Shaddick, Rachel Charlton, Charlotte Cavill, Richard Holland, Irini Flouri

J Rheumatol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rheumatoid arthritis patients on persistent moderate disease activity on biologics have adverse 5-year outcome compared to persistent low-remission status and represent a heterogeneous group.
Irini Genitsaridi, Irini Flouri, Dimitris Plexousakis, Konstantinos Marias, Kyriaki Boki

Arthritis Res Ther· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and Implementation of a Pilot Registry for Monitoring the Efficacy and Safety of Novel Therapies in Patients with Systemic Lupus Erythematosus.
Christina Adamichou, Irini Flouri, Antonios Fanouriakis, Myrto Nikoloudaki, Dionysios Nikolopoulos

Mediterr J Rheumatol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: real world data from 328 patients.
Konstantinos Thomas, Irini Flouri, Argiro Repa, Kalliopi Fragiadaki, Petros P Sfikakis

Clin Exp Rheumatol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence.
Irini D Flouri, Theodora E Markatseli, Kyriaki A Boki, Ioannis Papadopoulos, Fotini N Skopouli

J Rheumatol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liver safety of non-tumour necrosis factor inhibitors in rheumatic patients with past hepatitis B virus infection: an observational, controlled, long-term study.
Ioannis Papalopoulos, Antonis Fanouriakis, Nikolaos Kougkas, Irini Flouri, George Sourvinos

Clin Exp Rheumatol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment with the first TNF inhibitor in rheumatoid arthritis patients in the Hellenic Registry of Biologic Therapies improves quality of life especially in young patients with better baseline functional status.
Nadia Boubouchairopoulou, Irini Flouri, Alexandros A Drosos, Kyriaki Boki, Loukas Settas

Clin Exp Rheumatol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival.
Irini Flouri, Theodora E Markatseli, Paraskevi V Voulgari, Kyriaki A Boki, Ioannis Papadopoulos

Semin Arthritis Rheum· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis